Atezolizumab/Tecentriq ELISA Kit from Alpha Diagnostic
Checkpoint inhibitors are a critical aspect of immuno-oncology and enable researchers to investigate new therapeutic approaches that utilise the immune system’s ability to fight cancer. PD-L1 inhibitors such as Atezolizumab (also referred to by the commercial name Tecentriq) are widely investigated in tumour immune evasion and treatment response. The Atezolizumab/Tecentriq ELISA Kit, developed by Alpha Diagnostic and distributed by 2BScientific Limited, offers researchers a highly specific and reproducible method for quantifying Atezolizumab in biological mediums, including serum, plasma, and cell culture supernatants.
This indirect ELISA uses a recombinant human PD-L1-coated plate to selectively capture Atezolizumab, resulting in high-sensitivity detection and quantification in tandem with consistent performance and reduced lot-to-lot variability. The kit includes all required reagents and is suitable for both single-run and repeated use across extended studies. In addition to its species-independent design enhancing versatility, it supports applications across both human and preclinical research models, making it a powerful option for researchers looking for dependable results.
Applications in Immune Checkpoint Research
Atezolizumab is a humanised IgG1 antibody that targets PD-L1, blocking its interaction with PD-1 and CD80. By disrupting this immunosuppressive pathway, it enhances T cell activity, therefore improving anti-tumour immunity. The ELISA kit is well suited to studies assessing immune reactivation, tumour resistance pathways, and potential synergy with combination therapies.
The Atezolizumab/Tecentriq ELISA Kit is a necessary tool for researchers studying immune modulation and PD-L1 checkpoint inhibition in oncology. The kit provides accurate quantification of Tecentriq, meaning that the kit supports a plethora of applications, including pharmacokinetic studies, therapeutic distribution profiling, and monitoring of antibody clearance in preclinical studies.
Supporting Translational and Preclinical Studies
Whether used in early-stage development or translational research, the Atezolizumab/Tecentriq ELISA Kit provides the precision and reliability needed to quantify checkpoint inhibitor levels with accuracy. Its compatibility with multiple species and sample types makes it an ideal option for researchers doing longitudinal studies and cross-platform analyses. For laboratories investigating PD-L1’s role in cancer biology, this kit provides the sensitivity and robustness required to generate high-quality, actionable data.
